The MMWR Recommendations and Reports, "Pertussis Vaccination:
Use of Acellular Pertussis Vaccines Among Infants and Young
Children -- Recommendations of the Advisory Committee on
Immunization Practices (ACIP)," contained an error. On page 5,
Table 1 provides incorrect information about the antigenic content
of the vaccine manufactured by Connaught (US)/BIKEN
(Tripedia{Registered}). Each dose of Tripedia{Registered} contains
23.4 ug of filamentous hemagglutinin (FHA) in addition to 23.4 ug
of inactivated pertussis toxin (PT). Tripedia{Registered} contains
no pertactin (Pn).
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
